Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467271 · ClinicalTrials.gov registry record
Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
A clinical trial, sponsored by Guerbet.
- Completed
- Registry status
- 540
- Enrollment target
NCT01467271: Completed study, sponsored by Guerbet.
NCT01467271 is a clinical trial that has completed, run by Guerbet. The registered enrollment target is 540 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01467271 has completed, sponsored by Guerbet.
- COMPLETED
- Registry status
- 540 participants
- Enrollment target
Study Summary
The main purpose of this study is to prospectively estimate the incidence of Nephrogenic Systemic Fibrosis (NSF) in patients with moderate to severe renal impairment after administration of Dotarem®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-06 |
What the finished NCT01467271 record still lists
NCT01467271 is an observational study that tracks outcomes without assigning an intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01467271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01467271 about?
NCT01467271 is a clinical study titled "Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration". The main purpose of this study is to prospectively estimate the incidence of Nephrogenic Systemic Fibrosis (NSF) in patients with moderate to severe renal impairment after administration of Dotarem®
What is the current status of trial NCT01467271?
This trial is currently completed. The enrollment target is 540 participants. The study started on 2011-05. Estimated completion is 2017-06.
Who is sponsoring clinical trial NCT01467271?
This trial is sponsored by Guerbet, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia